DBV Technologies (FRA:DBV) ROE % Adjusted to Book Value : -73.13% (As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is DBV Technologies ROE % Adjusted to Book Value?

DBV Technologies's ROE % for the quarter that ended in Mar. 2024 was -87.02%. DBV Technologies's PB Ratio for the quarter that ended in Mar. 2024 was 1.19. DBV Technologies's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was -73.13%.

DBV Technologies ROE % Adjusted to Book Value Historical Data

The historical data trend for DBV Technologies's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DBV Technologies ROE % Adjusted to Book Value Chart

DBV Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-20.25

-57.10

-36.25

-43.77

-31.42

DBV Technologies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-25.31	-25.99	-23.42	-22.90	-73.13

Competitive Comparison of DBV Technologies's ROE % Adjusted to Book Value

For the Biotechnology subindustry, DBV Technologies's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DBV Technologies's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DBV Technologies's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where DBV Technologies's ROE % Adjusted to Book Value falls into.

DBV Technologies ROE % Adjusted to Book Value Calculation

DBV Technologies's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-42.73%	/	1.36
	=	-31.42%

DBV Technologies's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-87.02%	/	1.19
	=	-73.13%

DBV Technologies ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of DBV Technologies's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

DBV Technologies (FRA:DBV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DBV Technologies SA (FRA:DBV) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

DBVT:USA 0QAJ:UK DBV:France DBV:Germany

Address

177-181 avenue Pierre Brossolette, Montrouge, FRA, 92120

Website

http://www.dbvtechnologies.com

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node in order to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.